Table 2.
Adjusted risk for non-survivors and survivors among SARS-CoV-2-positive veterans by indicated post-index medication use and hospitalization status.
| Post-Index | Non Survivors ^ |
Survivors ^ | Multiplicity Corrected ‡ | ||
|---|---|---|---|---|---|
| Medication * | n (%) | n (%) | aRR (95% CI) † | p-Value | |
| Hospitalized (N = 7845) | |||||
| Vitamin D | Corticosteroids | ||||
| − | + | 534 (48) | 2615 (39) | 1.0 Referent | --- |
| − | − | 553 (50) | 3787 (56) | 0.66 (0.58–0.74) | <0.0001 |
| + | + | 15 (1) | 149 (2) | 0.51 (0.27–0.94) | 0.031 |
| + | – | 11 (1) | 181 (3) | 0.30 (0.16–0.58) | 0.0004 |
| Non-hospitalized (N = 18,663) | |||||
| Vitamin D | Corticosteroids | ||||
| − | + | 69 (14) | 2137 (12) | 1.0 Referent | --- |
| − | − | 413 (83) | 15,381 (85) | 0.94 (0.71–1.2) | 0.66 |
| + | + | 6 (1) | 113 (1) | 2.5 (0.90–7.1) | 0.078 |
| + | – | 11 (2) | 533 (3) | 0.48 (0.22–1.1) | 0.078 |
^ Non-referent group of the indicated comparison factor. * Systemic administration by mouth or intramuscular injection. † Adjusted for Age (≤60, 61–70, 71–80, >80), Alcohol Use Disorder (Yes, No), BMI (<18.5, 18.5–24.9, 25–29.9, ≥30), Charlson Comorbidity Index (0, 1–2, 3–4, 5+), Current Smoker (Yes, No), Location (Pacific-Mountain, Mid-West/Continental, East Coast), Race (White, Black, Other Race), Sex (Male, Female), and Time (March, April–September). ‡ Subset analyses corrected for multiplicity using the Hochberg step-up procedure for multinomial comparisons. aRR = Adjusted relative risk; BMI = body mass index (kg/m2); CI = confidence interval.